alpha(2)-Adrenoceptor involvement in the in vitro inhibitory effect of citalopram on a subpopulation of rat locus coeruleus neurons

Eur J Pharmacol. 2005 Jul 4;517(1-2):51-8. doi: 10.1016/j.ejphar.2005.05.033.

Abstract

The aim of the present study was to investigate the modulation of locus coeruleus neurons by the selective serotonin (5-HT) reuptake inhibitor citalopram using single-unit extracellular recordings in rat brain slices. Citalopram inhibited the activity of a subpopulation of locus coeruleus neurons; thus 10 microM citalopram inhibited neurons by 53+/-17% (5 out of 15 cells), whereas the inhibition due to 100 microM was 64+/-4% (32 out of 42 cells). This effect was partially reversed (47+/-11%) by the alpha(2)-adrenoceptor antagonist idazoxan (10 microM), whereas it was unaffected by antagonists for 5-HT(1A), 5-HT(2,) and 5-HT(3) receptors, and mu opioid receptors. 5-HT (50 or 200 microM), the 5-HT(1A) receptor agonist 8-OH-DPAT (+/-)-8-hydroxy-2-(DI-n-propyl-amino) tetralin hydrobromide, 10 microM) and the 5-HT(2) receptor agonist DOI ([+/-]-2,5-dimetoxy-4-iodoamphetamine) hydrochloride, 10 or 30 microM) also inhibited a subpopulation of locus coeruleus cells. In addition, citalopram but not 5-HT, enhanced by 1.7 fold the inhibitory effect of noradrenaline. Long-term treatment with citalopram (20 mg/kg/day) did not modify the effect of noradrenaline and bromoxidine. Taken together, our results indicate that citalopram exerts an inhibitory effect on locus coeruleus noradrenergic neurons. alpha(2)-adrenoceptor activation may underlie this effect as a result of elevated levels of noradrenaline in the synaptic cleft.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 8-Hydroxy-2-(di-n-propylamino)tetralin / pharmacology
  • Action Potentials / drug effects
  • Adrenergic alpha-2 Receptor Agonists
  • Adrenergic alpha-2 Receptor Antagonists
  • Adrenergic alpha-Agonists / pharmacology
  • Adrenergic alpha-Antagonists / pharmacology
  • Amphetamines / pharmacology
  • Animals
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacology
  • Brimonidine Tartrate
  • Citalopram / pharmacology*
  • Dose-Response Relationship, Drug
  • Duloxetine Hydrochloride
  • Idazoxan / pharmacology
  • In Vitro Techniques
  • Locus Coeruleus / cytology
  • Locus Coeruleus / drug effects*
  • Locus Coeruleus / physiology
  • Male
  • Methiothepin / pharmacology
  • Naloxone / pharmacology
  • Narcotic Antagonists / pharmacology
  • Neurons / drug effects*
  • Neurons / physiology
  • Norepinephrine / pharmacology
  • Oxazines / pharmacology
  • Piperazines / pharmacology
  • Piperidines / pharmacology
  • Pyridines / pharmacology
  • Quinoxalines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Adrenergic, alpha-2 / physiology*
  • Receptors, Opioid, mu / antagonists & inhibitors
  • Selective Serotonin Reuptake Inhibitors / pharmacology
  • Serotonin / pharmacology
  • Serotonin Antagonists / pharmacology
  • Serotonin Receptor Agonists / pharmacology
  • Thiophenes / pharmacology

Substances

  • Adrenergic alpha-2 Receptor Agonists
  • Adrenergic alpha-2 Receptor Antagonists
  • Adrenergic alpha-Agonists
  • Adrenergic alpha-Antagonists
  • Amphetamines
  • Bridged Bicyclo Compounds, Heterocyclic
  • Narcotic Antagonists
  • Oxazines
  • Piperazines
  • Piperidines
  • Pyridines
  • Quinoxalines
  • Receptors, Adrenergic, alpha-2
  • Receptors, Opioid, mu
  • Serotonin Antagonists
  • Serotonin Receptor Agonists
  • Serotonin Uptake Inhibitors
  • Thiophenes
  • Citalopram
  • alpha-phenyl-1-(2-phenylethyl)-4-piperidinemethanol
  • Serotonin
  • Naloxone
  • Brimonidine Tartrate
  • Methiothepin
  • N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide
  • azasetron
  • 8-Hydroxy-2-(di-n-propylamino)tetralin
  • Duloxetine Hydrochloride
  • 4-iodo-2,5-dimethoxyphenylisopropylamine
  • Norepinephrine
  • Idazoxan